Jan, 2001. Other pathogens [online]. Seacroft and St James's University Hospitals, UK. Available from http://www.cysticfibrosismedicine.com

With the widespread use of antibiotics and dramatic improvement in patients survival, newer organisms, such as Stenotrophomonas maltophilia (Denton et al, 1996; Denton et al, 1998), Alcaligenes species (Dunne & Moisch, 1995), atypical mycobacterium (Torrens et al, 1998) and methicillin resistant Staphylococcus aureus (MRSA) (Thomas et al, 1998; Report of Combined Working Party, 1998) are becoming more widespread. They may be associated with either simple colonisation or respiratory exacerbations.

For more details see CF (UK) Trust antibiotic consensus section

References

Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996; 15: 402-405

Denton M, Todd NJ, Kerr KG, Hawkey PM, Littlewood JM. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens of patients with cystic fibrosis and associated environmental samples. J Clin Microbiol 1998; 36: 1953-1958

Dunne WM Jr, Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element sequence polymerase chain reaction. Clin Infect Dis 1995; 20: 836-841

Report of a combined working party of the British Society for Antimicrobial Chemotherapy, the Hospital Infections Society and the Infection Control Nurses Association. Revised guidelines for control of methicillin-resistant Staphylococcus aureus infection in hospitals. J Hosp Infect 1998; 39: 253-290

Thomas SR, Gyi KM, Gaya H, Hodson M. Methicillin resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect 1998; 40: 203-209

Torrens JK, Dawkins P, Conway SP, Moya E. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998; 53: 182-185

Copyright © cysticfibrosismedicine